High expression of Zinc-finger protein X-linked promotes tumor growth and predicts a poor outcome for stage II/III colorectal cancer patients
Metrics: PDF 2083 views | HTML 2311 views | ?
Xuebing Yan1,*, Zezhi Shan1,*, Leilei Yan1, Qingchao Zhu1, Liguo Liu1, Bing Xu2, Sihong Liu2, Zhiming Jin1, Yuping Gao3
1Department of General Surgery, The Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China
2Department of Medicine, Soochow University, Suzhou, Jiangsu Province, China
3Center for Reproductive Medicine, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
*These authors have contributed equally to this work
Zhiming Jin, e-mail: [email protected]
Yuping Gao, e-mail: [email protected]
Keywords: colorectal cancer, ZFX, tumor growth, prognosis, DUSP5
Received: September 15, 2015 Accepted: January 29, 2016 Published: February 21, 2016
Zinc-finger protein X-linked (ZFX) was recently identified as a novel oncoprotein in several human malignancies. In this study, we examined the correlation between ZFX expression and the clinical characteristics of stage II/III CRC patients, as well as the molecular mechanism by which ZFX apparently contributes to CRC tumor progression. Using immunohistochemistry, we detected expression of ZFX in CRC tissues collected from stage II/III patients and determined that its expression correlated with tumor differentiation and stage. Survival analysis indicated that patients with high ZFX expression had poorer overall and disease-free survival. ZFX knockdown in SW620 and SW480 CRC cells significantly inhibited cell proliferation and colony formation, enhanced apoptosis and induced cell cycle arrest. It also enhanced the sensitivity of CRC cells to 5-Fu. In a xenograft model, ZFX knockdown suppressed in vivo CRC tumor growth. Microarray analysis revealed the primary target of ZFX to be DUSP5. Whereas ZFX knockdown increased DUSP5 expression, DUSP5 knockdown rescued ZFX-mediated cell proliferation in ZFX knockdown cells. These findings demonstrate that ZFX promotes CRC progression by suppressing DUSP5 expression and suggest that ZFX is a novel prognostic biomarker and potentially useful therapeutic target in stage II/III CRC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.